PRELIMINARY ANALYSIS FOR THE USE OF BIOLOGICALS IN THE TREATMENT OF RHEUMATOID ARTHRITIS
Keywords:Rheumatoid arthritis, Treatment, Biological drugs
Introduction: Rheumatoid arthritis (RA) is treated with conventional and biological disease-modifying drugs (DMARDs). Objectives: To compare the survival of biological drugs used for the treatment of RA patients. Methods: Retrospective study of medical records of patients who used biological medication for the treatment of RA from January 2020 to January 2022 and this was suspended. Data on the causes of withdrawal, duration of use, epidemiological, clinical and comorbid data were collected. Results: The main reason for discontinuity was failure followed by side effects. Infliximab and adalimumab had the highest survival. BMI (body mass index) and smoking, sex and age did not interfere in this survival. Conclusion: Failure is the most common cause of biological discontinuity. Among the factors studied (smoking, BMI, age and gender) it was not possible to identify a variable that was associated with failure.
How to Cite
Copyright (c) 2023 Alexia Ribeiro Silva , Guilherme Spezia Dalla Costa , Barbara Stadler Kahlow , Thelma Larocca Skare
This work is licensed under a Creative Commons Attribution 4.0 International License.
Data statement is contained in the manuscript